Arcus Biosciences RCUS Other — Total revenues

Other product segments

Similar metrics at other companies

PRGOther revenue — Total revenues

$39.4M+134%

FTAIOther revenue — Total revenues

$6.21M+19,923%

VIROther revenue — Total revenues

$0-100%

VSTTotal other revenues — Total revenues

-$2.04B+21.5%

WSCOther leasing-related revenue — Total revenues

$14.53M+21.6%

HRIService and other revenue — Total revenues

$10M+11.1%

FAQ

What is Arcus Biosciences's other — total revenues?

Arcus Biosciences (RCUS) reported other — total revenues of $6M in Q2 2026.

What is the long-term trend for Arcus Biosciences's other — total revenues?

Over 3 years (2022 to 2025), Arcus Biosciences's other — total revenues has grown at a -100.0% compound annual growth rate (CAGR), from $5M to $0.

What does other — total revenues mean?

This metric represents the total revenue generated from business activities or service offerings that fall outside the company's primary clinical-stage biopharmaceutical development pipeline. It captures income streams from ancillary operations, such as specialized research services or non-core licensing arrangements, which are not directly tied to the primary immuno-oncology product candidates. Monitoring this revenue helps investors assess the contribution of secondary business segments to the company's overall financial performance.